human
immunodefici
viru
identifi
caus
agent
acquir
immunodefici
syndrom
aid
year
pandem
infect
million
individu
kill
million
thirtythre
million
individu
current
live
make
diseas
major
worldwid
public
health
problem
unaid
natur
steril
immun
respons
never
describ
despit
decad
intens
research
vaccin
still
lack
mainli
due
high
abil
viru
escap
immun
respons
absenc
vaccin
combin
small
antivir
molecul
intens
use
control
infect
major
drug
revers
transcriptas
proteas
inhibitor
recent
new
molecul
target
fusion
step
integras
licens
clinic
use
despit
increas
life
expect
observ
advent
therapi
sever
side
effect
lack
adher
emerg
drugresist
viru
strain
still
limit
longterm
control
infect
envelop
viru
whose
genet
materi
consist
two
ident
rna
strand
code
structur
gene
gag
pol
env
well
accessori
gene
tat
rev
nef
vif
vpr
vpu
gag
gene
code
structur
protein
pol
code
viral
enzym
revers
transcriptas
integras
proteas
env
envelop
protein
precursor
subsequ
cleav
protein
assembl
surfac
trimer
spike
compos
three
monom
membraneembed
complex
free
two
protein
involv
viru
entri
repres
princip
target
humor
respons
upon
receptor
bind
glycoprotein
undergo
conform
chang
expos
loop
region
interact
chemokin
receptor
therebi
promot
viral
entri
figur
coreceptor
bind
lead
insert
fusion
peptid
cell
membran
creation
hairpin
loop
intermedi
final
fusion
viral
cell
membran
viral
capsid
enter
cell
genet
materi
releas
cytoplasm
viral
strain
use
one
coreceptor
enter
host
cell
classifi
accordingli
strain
strain
although
virus
broaden
coreceptor
usag
dualtrop
also
describ
virus
infect
macrophag
lymphocyt
mainli
associ
transmiss
contrast
virus
infect
tcell
tcell
line
often
appear
later
stage
infect
envelop
glycoprotein
compos
variabl
constant
region
sever
studi
demonstr
elicit
bind
effect
neutral
antibodi
impair
glycan
shield
steric
hindranc
constant
region
moreov
variabl
immunodomin
domain
shown
recogn
nonneutr
antibodi
nonetheless
estim
subject
develop
neutral
antibodi
ntab
appear
least
year
infect
infect
patient
develop
broad
neutral
respons
heterolog
viru
strain
among
patient
antibodi
aris
rare
tardili
thu
ineffici
control
viral
replic
howev
recent
identif
broadli
neutral
antibodi
bntab
map
epitop
fuel
interest
humor
immun
respons
review
overbaugh
better
understand
reason
underli
persist
viral
infect
despit
strong
sustain
immun
respons
one
hand
identifi
new
protect
immunogen
numer
studi
conduct
map
epitop
landscap
nonneutr
antibodi
isol
infect
patient
parallel
develop
new
molecul
antibodi
fragment
capabl
block
either
viral
protein
host
receptor
wide
investig
serv
purpos
phage
display
technolog
extens
exploit
field
repres
one
power
technolog
epitop
map
well
identif
ligand
bind
mani
type
target
bacteriophag
phage
bacteriainfect
virus
whose
dna
rna
genom
pack
capsid
compos
exclus
surfac
protein
principl
phage
display
reli
clone
exogen
dna
fusion
phage
genet
materi
allow
display
foreign
peptid
immunolog
biolog
compet
form
surfac
phage
capsid
protein
signific
phage
display
first
demonstr
filament
phage
fd
relat
phagemid
later
extend
lytic
bacteriophag
review
beghetto
phage
biopan
process
consist
iter
cycl
bind
wash
elut
step
lead
progress
select
phage
display
peptidesprotein
bind
target
interest
target
usual
immobil
solid
support
plastic
bead
even
cell
signific
advantag
technolog
phage
may
use
display
collect
sequenc
phage
librari
reach
billion
distinct
sequenc
phage
librari
construct
express
combinatori
peptid
proteinsimmunoglobulin
fragmentsvari
may
screen
mani
differ
purpos
includ
drug
discoveri
epitop
map
diagnosi
well
identif
therapeut
antibodi
phage
display
technolog
versatil
appli
differ
domain
research
allow
easi
handl
highthroughput
screen
billion
sequenc
afford
enabl
identif
linear
well
conform
epitop
appli
antibodi
target
numer
studi
describ
use
phage
display
technolog
field
report
classifi
four
main
applic
figur
review
intend
overview
differ
studi
conduct
use
phage
field
lay
special
emphasi
natur
phage
librari
use
target
display
mode
biopan
procedur
well
result
obtain
studi
classifi
accord
applic
describ
main
result
present
tabl
semin
paper
character
epitop
recogn
mab
direct
use
phage
display
technolog
publish
keller
et
al
screen
random
peptid
librari
rpl
bntab
target
loop
krkrihigpgrafi
figur
identifi
clone
present
gpxr
consensu
sequenc
tabl
mimotop
use
rabbit
immun
experi
elicit
neutral
respons
boot
et
al
later
investig
linear
epitop
recogn
mab
combin
competit
pan
biasedconstrain
librari
setup
favor
select
mimotop
residu
surround
gpgr
crown
motif
similar
present
use
competit
suggest
use
strainspecif
competitor
mab
broad
specif
select
strainspecif
mimotop
year
jelli
et
al
appli
phage
display
technolog
mab
recogn
loop
mn
strain
studi
rpl
construct
pan
mab
accord
two
differ
protocol
either
streptavidin
captur
phage
mix
biotinlabel
mab
sabio
pan
mab
immobil
microwel
micropan
phage
select
sabio
protocol
share
consensu
sequenc
yl
vli
gpgrxf
homolog
loop
micropan
protocol
allow
identif
sequenc
share
motif
two
also
identifi
sabio
pan
biopan
result
valid
peptid
array
hybrid
assay
hybrid
mab
peptid
contain
possibl
point
substitut
within
loop
sequenc
demonstr
phage
display
peptid
array
experi
identifi
critic
amino
acid
therebi
confirm
qualiti
rpl
valid
screen
perform
epitop
map
also
perform
monoclon
antibodi
mab
isol
asymptomat
patient
recogn
motif
within
loop
sequenc
krihigpgrafytt
bind
mab
viral
isol
present
mutat
sequenc
reveal
residu
within
recognit
motif
crucial
reactiv
biopan
rpl
result
select
sequenc
compat
minim
bind
site
g
fyt
infer
sequenc
align
clade
f
bound
mab
taken
togeth
data
bind
assay
well
phage
biopan
experi
demonstr
mab
epitop
span
side
loop
substitut
within
residu
locat
crown
loop
howev
toler
provid
format
induc
gpgr
crown
motif
allow
howev
one
except
report
boot
et
al
report
phe
trp
substitut
may
toler
absenc
parallel
grihald
et
al
construct
pan
rpl
mab
recogn
constrain
linear
epitop
loop
sever
clone
obtain
present
common
motif
rkh
xgr
mimick
crown
loop
sequenc
therebi
confirm
epitop
sequenc
mab
assess
reactiv
peptid
depriv
phage
scaffold
mimotop
highest
affin
mab
express
fusion
e
coli
alkalin
phosphatas
bind
phage
fusion
protein
mab
assess
elisa
western
blot
spr
assay
highlight
bind
independ
scaffold
although
interact
weaker
peptid
display
fusion
protein
format
phage
scaffold
anoth
studi
laisney
et
al
investig
minim
epitop
recogn
two
mab
interact
loop
whose
specif
strictli
restrict
lai
isol
screen
rpl
mab
allow
select
numer
sequenc
consensu
motif
bind
assay
synthet
peptid
show
mab
react
residu
lai
narrow
region
minim
epitop
deduc
mab
hyxrgp
wherea
mab
recogn
xq
rk
gp
motif
hy
nonaromat
aa
underlin
aa
toler
substitut
interestingli
essenti
qr
residu
locat
posit
correspond
qr
insert
locat
upstream
loop
gpgr
crown
motif
characterist
lai
isol
may
thu
explain
restrict
specif
two
mab
author
screen
rpl
mab
specif
loop
mn
isol
identifi
two
group
sequenc
repres
sequenc
first
group
hlgpgr
correspond
crown
loop
linear
epitop
two
sequenc
second
group
kaihri
kslhrh
show
homolog
linear
epitop
peptid
nevertheless
inhibit
interact
mab
even
abl
compet
bind
antibodi
indic
peptid
also
mimotop
peptid
conjug
klh
inject
separ
rabbit
peptid
abl
elicit
antibodi
partial
compet
homolog
peptid
confirm
peptid
antigen
immunogen
mimic
mn
loop
isol
bntab
interact
epitop
eldkwa
locat
mper
report
conley
et
al
character
epitop
biopan
rpl
immobil
ab
differ
sequenc
obtain
classifi
four
group
whose
consensu
motif
dkw
ldxw
ed
kr
w
eldkw
reveal
inform
residu
involv
ab
recognit
immun
attempt
eldkwa
peptid
fail
elicit
ntab
suggest
epitop
necessit
addit
residu
order
immunogen
therefor
menendez
et
al
screen
panel
librari
linear
constrain
peptid
mab
deduc
residu
flank
dkw
core
ctermin
side
region
import
highaffin
bind
mab
subsequ
construct
screen
two
phage
sublibrari
display
random
residu
either
upstream
downstream
dkw
core
isol
three
peptid
display
high
affin
librari
ala
substitut
delet
studi
reveal
clone
bound
accord
differ
mechan
data
led
author
postul
paratop
compos
two
bind
domain
either
recogn
dkw
core
strong
specif
multispecif
bind
residu
locat
cterminu
base
studi
addit
investig
recent
conduct
bntab
epitop
assess
import
structur
constraint
mab
recognit
linear
rpl
constrain
rpl
screen
antibodi
sequenc
select
rpl
contain
kr
w
core
motif
flank
residu
l
present
differ
frequenc
analysi
sequenc
represent
compar
estim
probabl
occurr
indic
trend
toward
enrich
sequenc
dkwa
ldkwa
throughout
pan
librari
sequenc
select
constrain
librari
contain
dkwa
ldkwa
result
demonstr
strong
epitop
specif
postul
menendez
display
epitop
sequenc
present
certain
structur
context
provid
constrain
peptid
immun
studi
perform
linear
constrain
form
peptid
mice
rabbit
result
inhibit
cell
fusion
sera
rabbit
immun
linear
peptid
rpl
screen
may
also
contribut
elucid
antigen
structur
purpos
stern
et
al
use
rpl
analyz
two
differ
mous
mab
recogn
nonoverlap
sequenc
residu
biopan
perform
allow
identif
mimotop
share
li
w
motif
ident
residu
domain
highlight
hxxixxlw
motif
compat
two
turn
comput
model
confirm
structur
place
residu
recogn
contigu
one
face
helix
secondari
structur
similarli
biopan
mab
yield
sequenc
trend
toward
motif
epitop
map
fnmwknd
sequenc
satisfi
helic
motif
fxxwxxd
studi
use
phage
display
predict
structur
domain
also
pinpoint
contact
residu
defin
surfac
helix
phage
display
also
appli
epitop
map
antibodydepend
cellular
cytotox
adcc
induc
mab
sinc
infect
cell
may
target
fc
receptorbear
effector
cell
interact
ab
screen
rpl
adccinduc
mab
result
identif
phage
txxfxxwxxd
rpl
fxdwxf
rpl
motif
homolog
domain
competit
assay
show
bind
mab
abrog
presenc
mimotop
contrast
heptapeptid
mimic
slightli
impair
bind
support
hypothesi
epitop
probabl
encompass
residu
addit
fxdwxf
motif
epitop
highli
conserv
among
circul
subtyp
might
use
induc
mab
antibodi
bntab
first
neutral
mab
select
phagedisplay
fab
antibodi
fragment
compos
one
constant
one
variabl
domain
heavi
vh
light
cl
vl
chain
link
togeth
librari
deriv
donor
see
section
antibodi
recogn
conform
epitop
overlap
site
attempt
precis
map
residu
interact
mab
rpl
provid
consensu
sequenc
previou
screen
cysteineenrich
peptid
librari
result
identif
two
sequenc
bear
sdl
motif
flank
one
two
cystein
residu
rekrwifsdlthtci
tclwsdlraqci
zwick
et
al
construct
two
sublibrari
share
sdl
motif
reflect
cystein
content
two
clone
peptid
hersymfsdlenrci
contain
uniqu
cystein
bound
fab
well
format
much
higher
affin
clone
moreov
phageborn
peptid
use
screen
fab
librari
identifi
revers
pan
experi
show
abl
select
fab
sequenc
correspond
confirm
specif
mimotop
toward
ab
peptid
immunogen
mice
rabbit
elicit
signific
crossreact
ab
titer
dorgham
et
al
attempt
map
epitop
rpl
two
random
join
allri
spacer
select
result
identif
clone
share
mvarsd
consensu
motif
ar
stand
aromat
residu
previous
observ
second
thirdgener
semirpl
contain
fix
consensu
motif
identifi
previou
pan
surround
random
residu
construct
mv
xlxvwxdexx
phagotop
phage
particl
display
particular
peptid
sequenc
select
given
target
obtain
first
second
third
gener
librari
show
increas
bind
affin
respect
phagotop
abl
compet
bind
trigger
product
ab
capabl
recogn
least
five
distinct
unrel
strain
contrast
correspond
peptid
abl
compet
bind
elicit
mab
discrep
phagotop
peptid
might
explain
constraint
impos
phage
scaffold
detail
character
bntab
conduct
mapitop
algorithm
develop
enshellseijff
et
al
facilit
identif
discontinu
epitop
approach
base
assumpt
collect
mimotop
recogn
given
antibodi
must
manner
reflect
antibodi
paratop
constrain
rpl
screen
select
sequenc
compar
obtain
previou
pan
experi
perform
although
similar
observ
mimotop
select
boot
et
al
consensu
wsdl
motif
observ
newli
identifi
mimotop
sequenc
isol
bonnycastl
et
al
mapitop
analysi
conduct
sequenc
well
peptid
set
isol
boot
bonnycastl
result
three
panel
predict
two
cluster
locat
peripheri
bind
site
time
linear
rpl
constrain
rpl
use
pan
experi
anoth
bind
site
mab
screen
rpl
result
select
singl
sequenc
wkpvvidf
screen
rpl
allow
identif
gpxepxgxwxc
consensu
motif
peptid
synthes
peptidepiii
fusion
protein
affin
assess
phagemab
bind
inhibit
assay
two
affin
peptid
aecgpaeprgawvc
aecgpyeprgdwtcc
use
immun
rabbit
elicit
antibodi
bind
recombin
monomer
nevertheless
gener
ab
seem
target
differ
epitop
sinc
unabl
compet
site
specif
mab
extrem
cterminu
form
pocket
may
interact
suggest
undergo
conform
chang
weaken
interact
upon
bind
absenc
avail
crystallograph
inform
ferrer
et
al
util
mous
mab
analyz
epitop
overlap
pocket
region
epitop
map
mab
achiev
crossblock
experi
suggest
ab
recogn
residu
screen
heptapeptid
rpl
mab
preincub
allow
recoveri
phage
present
axxkxrh
motif
homolog
residu
affin
studi
confirm
ala
ntermin
residu
mab
epitop
show
affin
increas
ctermin
residu
ad
mapitop
algorithm
design
enshellseijff
et
al
initi
develop
elucid
epitop
recogn
mab
screen
rpl
yield
sequenc
homolog
comparison
mimotop
structur
complex
mab
predict
candid
epitop
agreement
actual
contact
residu
valid
algorithm
rpl
librari
screen
mab
analysi
select
sequenc
predict
four
cluster
largest
correspond
genuin
epitop
algorithm
final
appli
mab
ab
unknown
epitop
compet
mab
bind
complex
mimotop
sequenc
analyz
produc
seven
cluster
one
accord
previou
mutat
analysi
imped
mab
bind
noteworthingli
reconstitut
phage
scaffold
epitop
capabl
bind
mab
success
identifi
linear
nearli
linear
epitop
boot
et
al
extend
use
phage
display
technolog
identif
epitop
recogn
mab
bind
discontinu
sequenc
one
ab
mab
bind
discontinu
epitop
involv
residu
within
region
isol
clade
b
c
e
f
pan
rpl
yield
sever
phage
share
trp
residu
studi
pan
rpl
mab
react
id
gklic
region
result
identif
sequenc
share
common
trp
within
motif
wgcx
kr
xlxc
fgxwfxmp
select
consensu
sequenc
howev
character
bntab
present
typic
featur
recogn
cluster
highmannos
oligosaccharid
attempt
identifi
peptid
immunogen
capabl
elicit
ab
menendez
et
al
screen
set
previous
describ
rpl
identifi
one
phagotop
specif
bind
crystal
structur
mab
complex
synthet
peptid
compar
structur
epitop
reveal
interact
ab
differ
two
ligand
result
show
peptid
select
rpl
pan
experi
structur
mimic
oligomannos
epitop
phagotop
use
rabbit
immun
experi
elicit
high
titer
peptidespecif
antibodi
crossreact
obtain
support
peptid
immunogen
mimic
mab
epitop
first
attempt
identifi
epitop
recogn
hivspecif
pab
perform
plasma
igg
two
ltnp
patient
tabl
use
linear
constrain
rpl
scala
et
al
identifi
mimotop
linear
immunodomin
id
gklic
region
domain
mimotop
immunogen
inject
mice
elicit
ntab
respons
moreov
mimotop
reduc
viraemia
undetect
level
immun
monkey
shown
subsequ
studi
year
similar
studi
conduct
one
ltnp
rpl
librari
cysteineconstrain
select
peptid
defin
id
epitop
csgklic
level
reactiv
phagotop
assess
panel
hiv
posit
plasma
evalu
plastic
polyclon
immun
respons
mount
infect
individu
later
palaciosrodriguez
et
al
evalu
impact
factor
highli
activ
antiretrovir
treatment
haart
ab
titer
select
peptid
mimick
id
epitop
csgklic
studi
mix
linear
well
linear
constrain
rpl
screen
individu
plasma
sampl
four
infect
patient
initi
haart
present
differ
titer
antigkl
antibodi
consensu
motif
cxxkxxc
obtain
linear
rpl
percentag
occurr
motif
select
sequenc
proport
antigkl
ab
titer
sampl
indic
ab
involv
select
consensu
motif
mice
immun
experi
two
mimotop
resembl
id
parent
epitop
well
pool
phage
elut
pan
experi
show
phage
elicit
reactiv
immun
phage
eluat
induc
strongest
recognit
find
indic
immunogen
properti
mimotop
differ
addit
open
possibl
immun
anim
differ
mimotop
combin
see
section
humbert
et
al
investig
immun
respons
eight
ltnp
patient
present
bntab
use
linear
constrain
rpl
identifi
epitop
recogn
plasma
igg
captur
tosylactiv
bead
pan
round
consist
posit
select
perform
ltnp
igg
follow
neg
select
igg
healthi
donor
homolog
select
sequenc
immunodomin
region
loop
gklic
region
observ
report
previou
studi
homolog
linear
motif
locat
near
loop
nnnt
downstream
id
gklic
region
avpw
motif
overlap
bntab
epitop
motif
also
identifi
addit
author
appli
softwar
compar
phage
insert
sequenc
protein
structur
file
rcsb
protein
data
bank
wwwpdborg
phage
pool
correspond
linear
loop
gklic
domain
wxxxw
motif
well
pool
repres
potenti
conform
epitop
select
mice
immun
assay
elicit
plasmaassoci
neutral
activ
primari
strain
highest
neutral
abil
obtain
mice
immun
mimotop
although
immun
potenti
conform
epitop
also
provid
modest
neutral
respons
similar
approach
use
author
rhesu
macaqu
infect
shiv
chimera
encod
env
clade
c
strain
present
broad
neutral
respons
homolog
shivc
well
heterolog
strain
differ
subtyp
biopan
yield
clone
similar
loop
ctermin
domain
region
id
gklic
region
id
region
mper
domain
remain
clone
show
signific
homolog
linear
region
analyz
softwar
allow
identif
discontinu
mimotop
locat
near
loop
crown
antibodi
bind
phagotop
affinitypurifi
subsequ
assay
demonstr
recognit
conformationdepend
immunofocus
immun
mice
prime
dna
vector
code
boost
pool
phage
particl
correspond
loop
cterminu
id
region
gklic
region
mper
domain
set
almost
mice
develop
antienv
ab
present
neutral
activ
dieltjen
et
al
appli
phage
display
technolog
identifi
epitop
potenti
involv
bntab
respons
individu
monitor
evolut
humor
respons
viral
escap
cours
infect
biopan
rpl
plasma
sampl
result
identif
differ
peptid
sequenc
half
sequenc
homolog
linear
epitop
ie
epitop
region
mper
domain
nwfnltqtlmpr
lentiviru
lytic
peptid
slxxlrl
peptid
share
homolog
domain
kxwwxa
crown
loop
analysi
level
reactiv
phage
group
sixyear
followup
sampl
reveal
differ
tempor
pattern
recognit
confirm
dynam
natur
immun
respons
interestingli
mper
region
epitop
retain
immunogen
properti
period
recent
studi
group
investig
antigen
landscap
subtyp
ainfect
individu
bntab
screen
rpl
librari
pool
sequenti
sampl
drawn
biopan
procedur
yield
sequenc
predict
repres
autolog
sequenc
loop
id
domain
cxgxlxctxnxp
followup
sampl
recognit
four
phage
group
show
differ
pattern
antibodi
reactiv
toward
id
region
fluctuat
slightli
plasma
sampl
reactiv
looplik
phage
decreas
time
contrast
loop
mimotop
recogn
emerg
reactiv
persist
env
sequenc
analysi
followup
sampl
show
tyr
mutat
loop
sequenc
coincid
emerg
antibodi
respons
sequenc
addit
author
highlight
neutral
activ
observ
sampl
partial
due
antibodi
recogn
mimotop
besid
multipl
report
use
rpl
character
humor
respons
env
protein
gupta
et
al
evalu
reliabl
use
target
antigen
gene
fragment
librari
identif
epitop
recogn
antibodi
elicit
rabbit
immun
end
construct
phage
librari
compos
dnasedigest
fragment
gag
dna
phagotop
obtain
first
pan
round
display
mainli
peptid
map
nterminu
gag
correspond
ctermin
region
gag
one
phagotop
map
central
region
gag
end
second
round
select
phage
display
longer
insert
aa
correspond
n
ctermin
region
gag
identifi
reveal
presenc
two
distinct
antigen
region
gag
studi
demonstr
genefrag
phage
display
could
use
identifi
epitop
target
polyclon
ab
although
occur
low
frequenc
human
antibodi
target
host
protein
involv
infect
report
immun
anim
given
potenti
valu
viral
entri
inhibit
gener
understand
mechan
rpl
screen
mab
gain
better
knowledg
epitop
tabl
murin
mab
rais
cell
transfect
seven
transmembranespan
domain
chemokin
receptor
one
main
coreceptor
recogn
common
epitop
locat
near
nterminu
mab
use
screen
constrain
rpl
phagotop
select
display
sequenc
chasiydfgsc
cphwlrdlrvc
preval
sequenc
isol
sequenc
show
homolog
residu
locat
nterminu
also
within
first
third
extracellular
loop
ecl
react
target
mab
either
phage
cyclic
peptid
linear
peptid
format
moreov
abl
bind
peptid
select
inhibit
bind
mab
cell
line
express
character
conform
epitop
recogn
addit
screen
round
rpl
perform
sequenc
hw
motif
homolog
cphwlrdlrvc
motif
select
mab
identifi
alascan
confirm
import
hw
motif
siyd
motif
previous
identifi
bind
anoth
murin
antibodi
mab
recogn
conform
epitop
second
ecl
explor
screen
linear
rpl
three
phagotop
isol
one
abl
inhibit
cell
infect
isol
correspond
peptid
fcaldgdfgwlapac
fuse
piii
phage
coat
protein
neutral
infect
mediat
jrfl
iiib
strain
fusion
protein
specif
bound
recogn
dosedepend
manner
three
chemokin
ligand
ie
rant
confirm
mimicri
six
year
later
anoth
screen
campaign
conduct
linear
rpl
ewqkeglvtlwl
sequenc
highaffin
bind
peptid
obtain
reveal
peptid
present
homolog
ntermin
ctermin
region
ala
substitut
tl
residu
confirm
crucial
role
bind
select
peptid
use
rabbit
immun
studi
elicit
ab
biolog
function
ie
inhibit
cell
fusion
pbmc
infect
cell
surfac
molecul
part
molecul
involv
syncytia
format
lymphocyt
mab
binder
inhibit
cell
fusion
poloni
et
al
appli
phage
display
technolog
map
epitop
therebi
identifi
domain
account
syncytia
format
linear
constrain
rpl
pan
mab
allow
select
linear
constrain
sequenc
ppfxyrk
consensu
motif
infer
sequenc
comparison
assign
epitop
recogn
residu
two
phagotop
inhibit
vitro
syncytia
format
one
retain
abil
peptid
format
confirm
role
syncytia
format
highlight
mimic
epitop
could
prevent
cellmedi
viral
propag
burton
et
al
first
report
construct
phagedisplay
fab
librari
bone
marrow
asymptomat
patient
high
titer
ab
librari
screen
recombin
iiib
isol
clone
display
high
affin
nm
select
one
fab
see
section
abl
neutral
mn
iiib
strain
differ
setup
ab
potent
neutral
ab
isol
date
featur
neutral
activ
primari
isol
test
concentr
could
achiev
passiv
immun
improv
affin
fab
submit
cdr
walk
procedur
involv
random
cdr
express
deriv
librari
express
phage
follow
screen
sequenti
cdr
walk
domain
perform
four
clone
chosen
detail
analysi
bind
affin
neutral
potenc
iiib
mn
isol
mutat
identifi
clone
highest
affin
bound
iiib
improv
affin
nm
compar
parent
fab
similarli
fab
abl
neutral
four
isol
insensit
parent
fab
cdr
walk
mutagenesi
strategi
pursu
subsequ
studi
improv
bind
affin
achiev
reach
pm
studi
first
demonstr
recombin
fab
devoid
typic
igg
contamin
residu
calpain
cleavag
featur
neutral
activ
similar
whole
igg
fab
fragment
easier
produc
smaller
size
allow
target
bind
site
access
fulllength
ig
led
construct
mani
fab
librari
elucid
immun
respons
identifi
therapeut
antibodi
extrem
high
bind
affin
also
appli
develop
immunotoxin
could
specif
kill
lymphocyt
author
engin
scfv
fuse
truncat
form
pseudomona
exotoxin
fv
fusion
immunotoxin
bound
mn
strain
affin
parent
fab
antibodi
specif
kill
cell
line
chronic
hivinfect
lymphocyt
cell
line
studi
provid
proofofconcept
high
affin
antibodi
dual
applic
sinc
may
use
neutral
potenc
also
carrier
antivir
compound
antibodi
obtain
screen
fab
librari
monomer
target
epitop
relat
domain
point
immunodomin
epitop
expedit
identif
ntab
direct
weakli
immunogen
epitop
strategi
call
epitopemask
appli
sever
studi
biopan
approach
design
mask
particular
epitop
antibodi
ligand
direct
region
interest
prior
addit
phage
librari
ditzel
et
al
pan
fab
librari
asymptomat
patient
immobil
recombin
identifi
two
domin
clone
target
site
two
fab
incub
mask
respect
epitop
pan
librari
repeat
highlight
base
sequenc
similar
four
group
fab
recogn
affin
rang
nm
epitop
map
one
repres
fab
group
show
bind
three
clone
influenc
loop
site
affect
glycosyl
statu
furthermor
one
fab
featur
broad
neutral
spectrum
variou
strain
author
perform
epitop
mask
use
differ
select
strategi
fab
phage
librari
first
strategi
involv
mask
site
epitop
either
solubl
ab
fab
select
recogn
region
fab
isol
abcaptur
classifi
four
differ
group
fab
target
region
similarli
fab
isol
ii
fab
direct
region
iii
fab
recogn
loop
iv
fab
direct
loop
region
similar
neutral
fab
isol
ditzel
et
al
multipl
epitop
mask
conduct
mask
one
fab
select
prior
phage
addit
lead
identif
two
fab
isol
fab
bound
target
affin
rang
nm
howev
fab
target
weakli
immunogen
region
poorli
neutral
recent
koefo
et
al
investig
ab
repertoir
circul
iggbear
b
cell
patient
construct
phage
display
fab
librari
unselect
cell
cell
preselect
immobil
pan
select
higher
number
phagotop
preselect
librari
clone
unselect
librari
recogn
loop
clone
preselect
librari
target
bs
epitop
encompass
region
fab
display
signific
differ
respect
epitop
specif
affin
neutral
abil
compar
fab
obtain
bone
marrow
librari
unabl
neutral
result
accord
previou
find
parren
et
al
conclud
major
circul
specif
antibodi
elicit
viral
debri
therefor
devoid
neutral
activ
antibodi
recogn
amino
acid
isol
patient
suffer
system
lupu
erythematosu
autoimmun
diseas
howev
whether
antibodi
neutral
known
prompt
karl
et
al
quantifi
ab
exist
scfv
phagedisplay
librari
pbmc
lupussuff
patient
biopan
select
clone
bind
region
site
one
clone
neutral
primari
isol
clade
b
c
rang
subset
antibodi
shown
hydrolyz
mechan
analog
serin
proteas
nucleophil
region
respons
activ
local
light
chain
librari
light
chain
prepar
three
lupu
patient
screen
electrophil
analogu
residu
isol
antibodi
capabl
bind
hydrolyz
one
light
chain
clone
select
cleav
substrat
well
fulllength
engin
ab
compos
light
chain
coupl
heavi
chain
might
provid
ab
antivir
proteolyt
activ
advantag
reduc
antibodi
format
also
explor
natur
occur
smaller
antibodi
addit
convent
antibodi
camelid
also
produc
antibodi
devoid
light
chain
figur
heavychain
antibodi
hcab
lack
domain
bind
specif
provid
variabl
heavychain
domain
hcab
vhh
nanobodi
cdr
region
nanobodi
averag
longer
cdr
convent
ab
display
protrud
conform
therebi
easili
bind
cleft
activ
site
nanobodi
success
use
pan
variou
pathogen
review
vanlandschoot
forsman
et
al
immun
llama
recombin
subtyp
bc
three
differ
pan
strategi
variou
result
select
three
nanobodi
neutral
activ
limit
panel
clade
b
c
strain
valu
rang
nanobodi
bound
affin
nm
inhibit
bind
well
mab
known
recogn
bind
site
last
least
compet
bind
followup
studi
koh
et
al
describ
familybas
approach
produc
nanobodi
similar
use
degener
oligonucleotid
anneal
last
six
codon
framework
fr
primer
amplifi
sublibrari
relat
vhh
clone
properti
similar
parent
vhh
phagotop
test
abil
neutral
clade
b
clade
c
strain
test
vhh
display
similar
neutral
activ
clade
b
virus
three
differ
neutral
profil
broad
intermedi
narrow
potenc
observ
clade
c
type
strain
breadth
neutral
potenc
appear
correl
presenc
yyd
motif
c
terminu
ydd
motif
introduc
within
bind
affin
increas
neutral
clade
c
strain
increas
studi
first
demonstr
bntab
elicit
immun
anim
vhh
stabl
produc
rel
low
cost
promis
inhibitor
receptor
recogn
residu
locat
within
region
engin
cell
receptor
appli
identifi
variant
better
affin
therebi
display
inhibitori
properti
krykbaev
et
al
construct
phagedisplay
librari
variant
gener
errorpron
pcr
screen
five
clone
increas
affin
present
mutat
within
domain
identifi
clone
inhibit
entri
rang
phage
display
technolog
use
improv
affin
mab
loop
epitop
also
identifi
phage
display
thompson
et
al
express
mab
scfv
phage
combin
vh
chain
nonimmun
pbl
repertoir
prior
pan
peptid
contain
loop
sequenc
addit
shuffl
region
combin
spike
ie
introduct
random
mutat
result
identif
four
key
residu
could
mutat
improv
ab
affin
sublibrari
four
codon
simultan
mutat
construct
biopan
allow
select
one
scfv
improv
kd
mab
epitop
two
neutral
fab
fab
loop
fab
obtain
screen
fab
librari
recombin
reach
rang
ferrer
harrison
screen
constrain
rpl
identifi
two
peptid
rpl
first
sequenc
rinnipwseamm
inhibit
well
bind
second
peptid
tspyedwqtylm
affect
interact
rather
enhanc
bind
peptid
investig
shown
inhibit
bind
monomer
valu
respect
peptid
also
inhibit
bind
ligand
trimer
envelop
glycoprotein
block
bind
nativ
coreceptor
specif
inhibit
infect
target
cell
vitro
entri
multistep
process
requir
success
bind
coreceptor
trigger
success
conform
chang
expos
transient
epitop
target
epitop
ntab
could
therefor
prevent
infect
proven
clinic
approv
fusion
inhibitor
enfuvirtid
identifi
receptorinduc
epitop
moulard
et
al
screen
fab
librari
construct
infect
patient
high
ntab
titer
complex
one
fab
clone
bound
sever
strain
low
nanomolar
affin
furthermor
bind
affin
significantli
increas
presenc
slightli
enhanc
competit
assay
panel
antibodi
target
differ
epitop
reveal
recogn
epitop
locat
close
vicin
coreceptor
bind
site
neutral
assay
isol
clade
b
c
f
g
demonstr
neutral
isol
potenc
compar
first
bntab
recogn
receptorinduc
epitop
identifi
date
select
ligand
epitop
murin
leukemia
viru
particl
carri
env
protein
dualtrop
strain
preincub
recent
use
screen
rpl
one
select
phagotop
hkqpwydywllr
display
sequenc
similar
bold
ntermin
extracellular
part
coreceptor
identifi
suggest
novel
potenti
lead
tyrosin
sulfat
phagotop
peptid
strongli
specif
bound
regardless
compet
mab
bind
epitop
sulfat
form
peptid
recogn
dualtrop
strain
inhibit
entri
high
micromolar
rang
salivari
protein
ixod
scapulari
inhibit
cell
activ
bind
molecul
region
may
overlap
bind
site
inhibit
mediat
ctermin
gpngqtcaeknkcvghipgc
sequenc
juncadella
et
al
thu
analyz
potenti
inhibitor
demonstr
inhibit
interact
subsequ
cell
fusion
gpngqtcaeknkcvghipgc
peptid
also
interact
identifi
amino
acid
interact
peptid
author
screen
rpl
isol
hvitplw
sequenc
homolog
il
tpl
motif
domain
highli
conserv
across
isol
final
map
interact
site
fulllength
protein
ctermin
domain
abl
bind
pcvkltplcvtlnct
peptid
within
region
addit
epitop
map
inhibitor
identif
phage
display
also
wide
appli
elucid
determin
initi
respons
antigen
particularli
import
differ
role
igm
igg
establish
infect
inde
known
bntab
igg
somat
hypermut
thu
difficult
elicit
contrast
igm
closer
germlin
antibodi
identif
specif
igm
could
relev
develop
vaccin
immunogen
studi
list
section
explor
emphas
import
initi
igm
respons
viral
strategi
skew
toward
nonneutr
infectionenhanc
antibodi
screen
igm
igg
fab
repertoir
construct
healthi
donor
demonstr
fab
isol
igm
abl
recogn
although
polyreact
display
low
affin
neutral
properti
sequenc
analysi
evidenc
select
fab
origin
differ
vh
germlin
gene
sever
studi
report
display
superantigen
properti
give
abil
bind
stimul
nonimmun
b
cell
secret
ig
vitro
interestingli
antibodi
famili
repres
immunoglobulin
gene
famili
healthi
adult
peripher
repertoir
infect
lead
alter
product
select
deplet
antibodi
toran
et
al
appli
phage
display
technolog
examin
compar
human
gene
involv
igm
igg
respons
identifi
correl
longterm
non
progress
two
igm
igg
phagedisplay
fab
librari
ltnp
high
igm
titer
construct
screen
sever
clone
select
igm
librari
three
clone
igg
librari
igm
fab
polyreact
bind
affin
micromolar
rang
igg
fab
specif
bound
affin
nanomolar
rang
expect
sequenc
analysi
show
igg
fab
origin
germlin
ab
igm
fab
display
vh
region
nucleotid
substitut
igg
fab
use
similar
dh
jh
segment
suggest
aros
isotyp
switch
addit
four
aminoacid
differ
sequenc
tgqwe
rggsi
propos
associ
affin
increas
higher
neutral
activ
igg
fab
ngml
igm
followup
studi
conduct
two
year
later
three
igg
fab
submit
revers
mutat
reconstitut
germlin
amino
acid
residu
higher
affin
neutral
abil
due
somat
mutat
region
germlin
gene
sequenc
provid
clue
ration
modif
cdr
human
antibodi
improv
affin
neutral
capac
igm
igg
isotyp
switch
gener
high
affin
neutral
nonneutr
antibodi
trigger
activ
igmproduc
b
cell
character
epitop
recogn
igm
assess
effect
ab
infect
chen
et
al
construct
fab
librari
blood
lymph
node
spleen
healthi
donor
librari
pan
env
ectodomain
contain
truncat
lack
transmembran
domain
cytoplasm
tail
clade
b
isol
allow
select
one
fab
clone
rel
high
bind
affin
differ
strain
sublibrari
deriv
clone
pan
differ
isol
result
select
clone
bind
high
affin
clade
b
f
rang
nm
nm
antibodi
weak
neutral
properti
isol
inhibit
case
even
enhanc
infect
isol
ab
whose
sequenc
rel
similar
germlin
ab
target
highli
conserv
epitop
locat
near
bind
site
coreceptor
bind
site
high
immunogen
capac
conserv
nonneutr
epitop
antibodi
could
divert
immun
system
actual
neutral
epitop
author
suggest
newli
identifi
mab
could
use
probe
character
conserv
nonneutr
enhanc
epitop
modifi
remov
candid
vaccin
immunogen
epitop
mask
strategi
section
might
appli
epitop
redirect
immun
system
elicit
antibodi
target
neutral
epitop
select
antibodi
close
resembl
germlin
antibodi
candid
sourc
bntab
author
construct
cordbloodderiv
igm
librari
submit
parallel
screen
env
sar
coronaviru
protein
bind
domain
rbd
solubl
hendra
viru
g
protein
sg
although
rbd
sg
antigen
provid
enrich
igm
librari
could
enrich
hiv
envbind
phagotop
result
accord
hypothesi
could
evolv
strategi
base
weak
absent
bind
antibodi
germlin
repertoir
present
epitop
unsuit
bind
somat
hypermut
antibodi
would
enabl
viru
escap
strong
immun
respons
zwick
et
al
construct
phagedisplay
fab
librari
posit
patient
except
bntab
patient
librari
screen
peptid
encompass
epitop
eldkwa
led
identif
mab
epitop
map
experi
base
synthet
peptid
recombin
protein
show
epitop
target
mab
locat
downstream
epitop
center
nfwdit
sequenc
mab
neutral
primari
isol
b
c
e
subtyp
enhanc
bind
potenc
fab
sublibrari
variant
engin
screen
mper
peptid
select
variant
display
increas
neutral
breadth
potenc
compar
parent
mab
bind
experi
coupl
competit
assay
reveal
mab
bound
waslwnwfditn
minim
epitop
overlap
epitop
asn
asp
residu
essenti
peptid
recognit
well
neutral
recent
phage
yeastdisplay
ab
librari
construct
patient
bntab
pan
peptid
contain
epitop
jrfl
two
mab
identifi
mutat
variant
neutral
higher
potenc
ala
substitut
indic
ab
recogn
dkw
core
epitop
two
addit
leucin
residu
locat
upstream
l
fusion
viral
host
membran
last
step
entri
requir
initi
insert
fusion
peptid
host
cell
membran
format
extend
prehairpin
intermedi
phi
n
ctermin
heptad
repeat
nhr
chr
collaps
form
sixhelix
bundl
nhr
form
trimer
coiledcoil
creat
groov
chr
bind
viral
cellular
membran
therebi
brought
close
proxim
enabl
fusion
figur
phi
format
nhr
chr
interact
may
thu
transient
target
compound
prevent
format
sixhelix
bundl
dominantneg
manner
one
compound
synthet
chr
mimic
enfuvirtid
hydrophob
pocket
locat
ntermin
peptid
trimer
groov
highli
conserv
among
sequenc
play
critic
role
membran
fusion
therefor
repres
select
target
inhibitor
eckert
et
al
use
particular
approach
call
mirrorimag
phage
display
identifi
dpeptid
target
hydrophob
pocket
approach
phage
librari
natur
l
peptid
screen
mirror
imag
target
synthes
dpeptid
symmetri
select
dpeptid
phagotop
sequenc
bind
natur
lform
target
main
advantag
dpeptid
lpeptid
inhibitor
resist
natur
proteas
enhanc
oral
bioavail
serum
halflif
first
studi
author
screen
constrain
rpl
dpeptid
sequenc
hydrophob
pocket
fuse
solubl
trimer
coiledcoil
pocketspecif
binder
consensu
motif
identifi
inhibit
cell
fusion
entri
cell
micromolar
rang
synthes
use
damino
acid
second
studi
author
construct
sublibrari
base
consensu
sequenc
identifi
first
studi
allow
select
sequenc
fourfold
potenc
increas
surprisingli
potent
peptid
motif
probabl
select
sublibrari
smaller
size
favor
compact
hydrophob
core
upon
bind
hydrophob
pocket
screen
second
gener
dpeptid
librari
led
select
pocketspecif
inhibitor
entri
pie
nm
dimer
trimer
form
respect
valu
nm
pm
third
studi
author
construct
phage
librari
base
core
sequenc
flank
two
random
amino
acid
xxcdypewqwlcxx
obtain
phage
h
ap
core
rke
l
consensu
sequenc
peptid
hpcdypewqwlcel
exhibit
broad
neutral
spectrum
even
effici
reach
nm
trimer
moreov
third
gener
display
broaden
inhibitori
potenc
resist
viral
variant
escap
mutant
requir
week
select
vitro
emerg
trimer
thu
promis
entri
inhibitor
may
use
topic
microbicid
conform
evid
ab
capabl
bind
highli
conserv
nhr
region
target
inhibitor
determin
whether
antibodi
fragment
could
target
determin
protein
miller
et
al
construct
phagedisplay
scfv
librari
screen
synthet
protein
mimick
construct
name
lack
one
three
chr
nhr
trimer
partial
expos
present
singl
bind
site
chr
mimic
scfv
librari
also
pan
compound
homotrimer
form
nhr
amino
acid
fuse
coiledcoil
peptid
therefor
repres
mimic
devoid
chr
trimer
author
identifi
scfv
block
entri
inhibit
infect
singlecycl
infect
assay
scfv
retain
properti
produc
whole
antibodi
found
bind
hydrophob
pocket
nhr
trimer
ala
scan
experi
reveal
crucial
role
residu
locat
hydrophob
pocket
interact
abl
neutral
least
five
isol
rang
nm
therebi
demonstr
hydrophob
pocket
nhr
trimer
access
bind
inhibitor
larg
igg
year
anoth
studi
demonstr
antibodi
bind
high
affin
specif
heptad
repeat
isol
synthet
fab
minimalist
librari
present
tyrser
random
cdr
recent
liu
et
al
took
advantag
result
construct
minimalist
fab
librari
domain
random
tyr
ser
screen
librari
mimic
select
fab
affin
specif
valu
compar
obtain
scfv
previous
describ
ab
huang
et
al
use
polypeptid
mimick
screen
rpl
select
sequenc
bear
hxx
nd
pf
motif
consensu
motif
synthes
peptid
inhibit
syncytia
format
fusion
inhibitor
also
identifi
screen
nonimmun
human
fab
librari
loui
et
al
screen
librari
antigen
compris
trimer
coiledcoil
nhr
fuse
sixhelix
bundl
respect
identifi
fab
target
ii
nhr
trimer
coiledcoil
iii
trimer
coiledcoil
antibodi
test
cell
fusion
inhibit
assay
two
potent
mab
belong
third
group
featur
two
year
later
librari
screen
antigen
two
clone
fab
inhibit
cell
fusion
one
fab
clone
select
also
effect
infect
neutral
assay
fab
bound
well
stabl
nhr
trimer
recogn
epitop
partial
overlap
hydrophob
pocket
target
ab
author
subsequ
demonstr
e
g
peptid
present
mutat
within
aa
residu
heptad
repeat
increas
tempor
window
viral
sensit
fab
therebi
synergist
enhanc
neutral
activ
fab
well
bntab
fab
sublibrari
creat
affin
matur
fab
loop
screen
select
three
fab
fab
enhanc
potenc
averag
decreas
neutral
breadth
followup
studi
demonstr
affinitypurifi
igg
rabbit
immun
inhibit
fusion
nelson
et
al
rescu
scfv
antibodi
librari
anim
three
binder
select
one
display
neutral
activ
parallel
complex
fab
librari
construct
posit
patient
ab
previous
isol
screen
librari
allow
isol
fab
scfv
fab
neutral
infect
panel
viral
strain
rang
nm
target
nhr
trimer
coiledcoil
presum
close
hydrophob
pocket
three
addit
ab
obtain
screen
antibodi
phage
librari
asymptomat
seroposit
patient
recombin
isol
asymptomat
seroposit
patient
bntab
report
elicit
bntab
monkey
demonstr
immunogen
epitop
expos
recombin
antigen
competit
antigen
pan
cap
biopan
approach
design
outcompet
phagotop
bind
immunodomin
region
multidomain
target
concomit
addit
excess
solubl
form
immunodomin
domain
use
mixtur
antigen
competitor
result
select
ab
display
broad
neutral
properti
recogn
conform
epitop
bound
weakli
antigen
trimer
nhr
two
studi
librari
pan
three
differ
isol
led
identif
ab
recogn
conform
epitop
ab
bind
nhr
trimer
coiledcoil
recogn
conserv
conform
epitop
neutral
isol
differ
clade
significantli
higher
potenc
competit
antigen
pan
approach
thu
allow
select
ab
recogn
conform
epitop
properli
fold
use
target
vpr
involv
nuclear
import
viral
preintegr
complex
pic
well
induct
apoptosi
cell
cycl
arrest
packag
virion
quantiti
similar
structur
protein
vpr
also
report
associ
numer
cellular
protein
glucocorticoid
receptor
transcript
factor
uracyl
dna
glycosylas
udg
investig
whether
vpr
may
use
dock
protein
deliv
antivir
compound
virion
bouhamdan
et
al
use
rpl
determin
common
motif
involv
interact
vpr
variou
ligand
screen
round
vpr
fusion
protein
pinpoint
sequenc
share
wxxf
motif
sinc
udg
contain
wxxf
sequenc
mutant
construct
confirm
import
motif
vpr
bind
cotransfect
experi
indic
wxxf
motif
might
use
deliv
fusion
protein
virion
new
dock
strategi
krichevski
et
al
conduct
studi
elucid
exact
role
vpr
contribut
nuclear
import
process
pic
aim
semisynthet
scfv
librari
screen
ntermin
aa
part
vpr
vprn
conjug
bsa
vprnbsa
purifi
scfv
fragment
featur
strong
specif
bind
vprn
sequenc
recogn
fulllength
vpr
inhibit
vprmediat
nuclear
import
indic
target
vpr
may
lead
develop
new
peptid
fight
viral
infect
phage
display
technolog
also
appli
identif
integras
inhibitor
desjobert
et
al
screen
rpl
recombin
integras
identifi
high
affin
phagotop
display
fhnhgkq
sequenc
peptid
format
sequenc
inhibit
strand
transfer
activ
compet
target
dna
provid
proofofconcept
also
valuabl
target
phage
display
interact
viral
transcript
activ
tat
human
subunit
posit
transcript
elong
factor
ptefb
complex
cooper
bind
complex
transactiv
respons
element
tar
rna
prerequisit
transcript
screen
rpl
fab
librari
tat
tar
element
use
phage
display
technolog
identifi
peptid
impair
tatmedi
replic
first
studi
conduct
pilkington
et
al
screen
fab
librari
construct
ab
repertoir
asymptomat
patient
select
fab
recogn
region
compris
amino
acid
tat
protein
conformationdepend
manner
mani
year
later
nonimmun
human
scfv
phagedisplay
librari
explor
identifi
peptid
bind
clone
recogn
cyclin
box
domain
interact
tattar
recognit
motif
trm
isol
pan
ntermin
amino
acid
express
intrabodi
antibodi
antibodi
fragment
express
intracellularli
one
scfv
inhibit
tatmedi
transactiv
without
impair
cellular
basal
transcript
induc
apoptosi
partial
inhibit
replic
cultur
cell
tar
rna
sequenc
adopt
specif
structur
recogn
basic
arginin
rich
motif
arm
tat
thu
repres
potenti
target
phage
display
screen
kolb
boiziau
screen
rpl
tar
rna
molecul
select
unexpectedli
sequenc
librari
latter
propos
aris
incomplet
enzym
restrict
construct
initi
librari
clone
character
peptid
format
display
tarspecif
bind
author
suggest
surprisingli
long
peptid
might
select
retriev
librari
present
conform
shorter
peptid
unabl
adopt
nucleocapsid
protein
process
gag
precursor
involv
protect
encapsid
viral
rna
lead
viral
assembl
interact
specif
secondari
structur
long
psi
rna
lener
et
al
screen
constrain
rpl
select
phagotop
share
ppx
de
r
consensu
motif
bind
experi
suggest
interact
involv
amino
acid
encompass
zinc
finger
domain
studi
identifi
inhibitor
viral
packag
also
conduct
rpl
screen
psi
rna
immobil
onto
streptavidinco
surfac
anneal
biotinyl
oligom
lead
select
peptid
character
hwwpww
motif
peptid
variant
present
motif
subsequ
synthes
effici
binder
shown
strongli
reduc
viru
releas
infect
cell
suggest
could
serv
lead
compound
develop
new
drug
similar
screen
campaign
conduct
psi
rna
coval
immobil
leav
secondari
structur
intact
fulli
access
screen
rpl
select
four
clone
either
whxt
hssxi
motif
assess
specif
dosedepend
bind
psi
rna
preval
sequenc
syqwwwhspqtl
express
fusion
maltosebind
protein
abl
compet
bind
psi
rna
confirm
valu
peptid
potenti
inhibit
compound
accessori
protein
nef
vif
import
role
viral
replic
infect
repres
interest
target
inhibitor
yang
et
al
demonstr
vif
abl
multimer
domain
critic
multimer
point
interest
target
impair
vifmedi
viral
replic
author
therefor
screen
rpl
librari
vif
select
phage
share
common
pxp
motif
four
sequenc
synthes
peptid
bound
cterminu
vif
high
affin
abl
inhibit
vifvif
well
vifhck
tyrosin
kinas
interact
moreov
peptid
inhibit
replic
cultur
cell
besid
identif
inhibitor
rpl
discoveri
ab
target
nef
vif
applic
intrabodybas
therapi
may
repres
altern
way
imped
viral
replic
recent
studi
yoshikawa
et
al
evalu
effect
two
differ
schedul
nef
vif
administr
mice
immun
prior
construct
scfv
phagedisplay
librari
result
demonstr
immun
protocol
influenc
complex
elicit
ab
repertoir
thu
success
identif
ab
specif
recogn
target
nanobodi
recogn
conform
epitop
react
high
affin
kd
nm
nef
protein
panel
n
p
group
isol
phage
display
vhh
repertoir
llama
immun
purifi
recombin
nef
protein
fragment
express
intrabodi
antinef
sdab
inhibit
import
biolog
function
nef
vitro
vivo
transgen
mice
first
step
cytotox
lymphocyt
ctl
activ
recognit
cell
receptor
tcr
antigenderiv
peptidemhc
class
complex
pmhc
date
studi
undertaken
examin
antigen
present
cellular
molecular
level
nunoya
et
al
screen
pool
scfv
librari
immunodomin
hlaa
restrict
ctl
epitop
within
nef
protein
rypltfgwcf
pan
procedur
yield
clone
bind
specif
nef
clone
abl
bind
nef
express
cell
surfac
retain
specif
express
reconstitut
whole
igg
recent
studi
first
address
identif
monoclon
antibodi
bind
specif
immunodomin
ctl
epitop
load
hla
class
molecul
revers
transcriptas
valuabl
target
compound
illustr
success
multipl
small
compound
use
haart
gargano
et
al
pan
phagedisplay
librari
synthet
combinatori
human
fab
fragment
recombin
rt
two
ab
fragment
specif
inhibit
rnadepend
dna
polymeras
rddp
activ
rt
identifi
fragment
also
inhibit
activ
avian
murin
retrovir
rt
well
human
dna
polymeras
prokaryot
dna
polymeras
lack
specif
ab
fragment
exploit
molecul
develop
panel
recombin
mab
react
differ
epitop
rt
ohba
et
al
immun
mice
recombin
rt
express
vaccinia
viru
vector
construct
phagedisplay
mice
fab
fragment
librari
biopan
recombin
rt
led
identif
two
fab
fragment
abl
strongli
inhibit
rddp
activ
rt
epitop
map
competit
elisa
show
recogn
epitop
similar
close
relat
epitop
target
mous
mab
previous
describ
author
two
year
later
semisynthet
phage
display
librari
human
scfv
random
heavi
light
chain
screen
recombin
rt
five
differ
scfv
ab
direct
rt
isol
three
inhibit
rddp
activ
rt
note
also
inhibit
rt
dnadepend
dna
polymeras
dddp
activ
synthesi
peptid
correspond
region
heavi
light
chain
show
heavi
chain
inhibit
rddp
activ
light
chain
peptid
effect
peptid
repres
smallest
antibodi
fragment
inhibit
rt
identifi
date
demonstr
repertoir
potenti
sourc
bioactiv
molecul
see
section
rev
key
regulatori
protein
oligomer
rev
bind
unsplic
singli
splice
viral
mrna
ensur
transport
cytoplasm
therebi
allow
translat
viral
gene
product
despit
consider
effort
structur
rev
poorli
character
sinc
rev
refractori
crystal
mainli
tendenc
form
insolubl
aggreg
absenc
structur
inform
phage
display
technolog
use
differ
author
map
domain
involv
interact
rev
network
partner
pilkington
et
al
identifi
two
revspecif
fab
fab
librari
deriv
ab
repertoir
asymptomat
patient
fab
direct
site
adjac
rev
basic
nuclear
local
signal
nl
residu
activ
domain
residu
two
year
later
jensen
et
al
screen
rpl
identifi
potenti
rev
peptid
antagonist
three
group
sequenc
share
srlxg
x
motif
group
share
rvv
x
motif
group
ii
featur
sequenc
similar
group
iii
obtain
three
clone
select
base
high
frequenc
occurr
group
strong
bind
affin
rev
group
iii
synthes
peptid
shown
retain
rev
bind
specif
recent
llama
nanobodi
librari
anim
immun
recombin
rev
allow
identif
revbind
nanobodi
one
prevent
disrupt
rev
multimer
interact
rev
ntermin
besid
inhibitor
discoveri
fab
recent
propos
crystal
chaperon
support
crystal
partner
lock
specif
conform
block
aggreg
stahl
et
al
describ
prepar
character
crystal
equimolar
complex
form
rev
chimer
rabbithuman
fab
select
phage
display
fab
complex
success
crystal
fab
shown
recogn
conform
epitop
ntermin
half
rev
structur
character
crystal
fabrev
complex
ongo
correspond
scfv
engin
may
properti
identifi
peptid
interf
capsid
assembl
sticht
et
al
screen
rpl
capsid
ca
protein
gener
proteolysi
gag
precursor
identifi
phagotop
whose
sequenc
could
classifi
four
group
one
sequenc
cai
capsid
assembl
inhibitor
compet
phagotop
bind
ca
inhibit
capsid
assembl
vitro
interact
cai
map
ca
amino
acid
addit
contact
helix
cai
inhibit
capsid
assembl
vivo
may
nevertheless
serv
tool
drug
screen
start
point
drug
design
base
cabind
properti
peptid
antibodi
fragment
select
mean
phage
display
may
also
use
diagnost
purpos
assess
divers
immun
respons
antigen
de
haard
et
al
construct
scfv
librari
pbl
posit
patient
present
antibodi
screen
librari
one
phagotop
recogn
epitop
within
bntab
epitop
ab
affin
nanomolar
rang
isol
importantli
shown
compet
plasma
sampl
northamerican
african
posit
patient
indic
antibodi
recogn
epitop
conserv
larg
panel
isol
might
suitabl
diagnost
applic
sinc
vaccin
candid
elicit
antibodi
react
posit
hiv
test
khurana
et
al
appli
phage
display
technolog
identifi
epitop
suscept
help
discrimin
success
immun
vaccine
seroconvert
construct
phage
librari
display
full
genom
screen
sera
newli
seroconvert
posit
individu
identifi
conserv
epitop
present
gag
part
vaccin
use
moment
establish
new
detect
test
name
selectest
demonstr
select
sensit
earli
detect
seroconvers
hiv
selectest
abl
detect
antibodi
epitop
newli
infect
patient
earli
week
infect
cc
chemokin
receptor
one
two
major
coreceptor
bind
three
differ
endogen
chemokin
rant
report
prevent
entri
interestingli
inhibit
bind
provid
almost
complet
protect
virus
minor
effect
normal
physiolog
function
cell
first
biopan
experi
target
perform
use
receptor
embed
paramagnet
proteoliposom
creat
proteoliposom
magnet
bead
ad
mixtur
synthet
lipid
detergentsolubil
receptor
captur
antibodi
reconstitut
membran
bilay
contain
pure
nativ
properli
orient
receptor
proteoliposom
use
biopan
experi
human
scfv
antibodi
librari
sever
antibodi
fragment
specif
bind
cell
identifi
year
steinberg
et
al
use
phage
display
technolog
select
human
rabbit
antibodi
prevent
export
cell
surfac
follow
rabbit
immun
gstnterm
fusion
protein
author
construct
phage
display
fab
librari
screen
antigen
initi
use
immun
phagotop
bind
strongli
specif
immobil
antigen
well
cell
identifi
express
scfv
human
success
replac
rabbit
light
heavi
chain
human
counterpart
one
human
antibodi
fragment
retain
strong
capac
parent
antibodi
isol
screen
intermedi
librari
express
intrabodi
scfv
effici
block
express
cell
surfac
hartley
et
al
develop
anoth
innov
effici
strategi
identifi
entri
inhibitor
base
ligand
variant
select
phage
display
review
et
al
strategi
phage
librari
display
randomli
mutat
ntermin
extend
chemokin
variant
xs
xssx
repres
either
p
construct
screen
cell
intracellular
phagotop
induc
receptor
intern
recov
two
variant
identifi
variant
display
higher
select
potent
inhibitori
abil
wildtyp
chemokin
character
demonstr
act
superagonist
potent
induc
intracellular
sequestr
less
potent
significantli
reduc
intracellular
calcium
signal
subsequ
studi
variant
optim
phage
display
biopan
select
variant
retain
high
anti
potenc
reduc
activ
three
success
gener
librari
repres
g
l
p
repres
g
l
construct
screen
previous
describ
three
interest
candid
produc
solubl
protein
display
highli
potent
antivir
activ
analogu
act
agonist
sequest
induc
signal
receptor
sequestr
induc
intern
without
trigger
gprotein
signal
altogeth
data
demonstr
antivir
activ
similar
molecul
identifi
phage
display
screen
reli
variou
mechan
action
shortli
identif
variant
zhang
et
al
report
altern
biopan
methodolog
reli
use
small
cyclic
biotinyl
peptid
mimick
extracellular
loop
identif
scfv
mous
phagedisplay
scfv
librari
incub
biotinylatedecl
peptid
eclbind
phage
specif
recov
use
streptavidinco
bead
among
scfv
identifi
three
clone
select
cyclic
peptid
inhibit
tropic
screen
rpl
also
appli
discoveri
small
peptid
target
receptorexpress
cell
vyroubalova
et
al
screen
partial
random
phage
librari
use
competit
elut
analogu
nm
select
uniqu
peptid
allrynpfyylsfsp
peptid
optim
ntermin
extens
exon
shuffl
biopan
appli
success
treatment
consist
preselect
use
low
amount
pm
discard
lowaffin
bind
phage
follow
classic
alkalin
elut
use
tea
competit
elut
contain
identifi
extend
peptid
lldstfftadallrynpfyylsfsp
inhibit
cell
fusion
parallel
wang
et
al
screen
fulli
random
rpl
use
acid
elut
identifi
phagotop
bind
specif
cell
share
afdwtfvpslil
sequenc
peptid
phage
format
sequenc
block
bind
neutral
mab
complet
inhibit
bind
chemokin
receptor
cxc
chemokin
receptor
second
major
coreceptor
bind
one
endogen
chemokin
ligand
also
express
surfac
numer
cancer
cell
type
underlin
high
valu
therapeut
target
despit
import
rel
success
phage
biopan
two
recent
studi
report
use
phage
display
search
inhibitor
jahnichen
et
al
isol
llamaderiv
vhh
bind
specif
inhibit
entri
viru
select
vhh
bind
exclus
function
properli
fold
receptor
llama
immun
cell
phage
librari
subsequ
construct
pbmc
immun
camelid
sever
phage
clone
inhibit
bind
label
chemokin
receptor
identifi
particular
two
vhh
show
low
nanomolar
affin
receptor
inhibit
entri
differ
cell
type
valu
rang
nm
dimer
form
biparatop
protein
increas
antivir
properti
valu
picomolar
rang
epitop
map
reveal
two
vhh
inhibit
mainli
bind
second
extracellular
loop
recent
use
peptid
correspond
particular
extracellular
loop
target
identifi
short
antagonist
screen
nonimmun
phage
librari
display
human
peptid
repertoir
sever
small
peptid
bind
peptid
specif
recogn
cell
identifi
notabl
one
peptid
typgri
act
antagonist
potenc
micromolar
rang
addit
target
host
receptor
studi
report
identif
peptid
antibodi
fragment
direct
host
protein
cell
surfac
determin
cd
intracellular
enzym
receptor
member
tumor
necrosi
factor
receptor
superfamili
ligand
involv
sever
biolog
process
includ
cell
prolifer
activ
product
cytokin
chemokin
infect
virus
propos
select
downregul
even
deplet
pool
cell
context
antibodi
bind
restor
downregul
might
interest
ellmark
et
al
identifi
set
antibodi
fragment
biopan
human
scfv
phage
librari
biotinyl
antigen
express
fulllength
one
antibodi
clone
suppress
infect
viru
probabl
induct
cc
chemokin
product
recent
protein
cellular
rna
helicas
involv
rna
unwind
shown
play
import
role
replic
protein
present
uniqu
region
alramkeng
respons
high
affin
bind
rna
garbelli
et
al
carri
biopan
experi
mix
linear
linear
constrain
rpl
peptid
mimick
region
interact
identifi
peptid
sdvptqv
block
replic
viru
besid
therapeut
purpos
phage
display
technolog
also
appli
fundament
studi
host
protein
particular
studi
focus
role
divers
autoimmun
repertoir
myelosuppress
appear
infect
individu
report
rubinstein
et
al
use
substract
biopan
procedur
immun
repertoir
seroposit
patient
author
select
fab
fragment
bind
specif
receptor
sequenc
bind
analys
antibodi
fragment
demonstr
heterogen
origin
autoimmun
repertoir
suggest
autoantibodi
might
gener
antigenspecif
driven
process
use
phage
proteas
cleavag
specif
profil
first
describ
matthew
well
phage
substrat
approach
reli
use
phage
particl
screen
enzym
substrat
instead
classic
binder
select
proteas
cleavag
profil
use
phage
take
advantag
natur
resist
phage
particl
proteolysi
phage
particl
display
random
peptid
immobil
solid
support
submit
proteolyt
elut
specif
liber
phage
present
peptid
correspond
proteas
cleavag
site
phage
substrat
approach
allow
thu
rapidli
determin
cleavag
profil
given
proteas
provid
optim
substrat
candid
use
lead
develop
specif
inhibitor
last
two
decad
phage
substrat
appli
larg
varieti
proteas
includ
proteas
pr
pr
homodimer
aspart
proteas
respons
nine
critic
cleavag
step
within
structur
gag
nonstructur
gagpol
polyprotein
proteas
recogn
substrat
residu
encompass
posit
schechter
berger
nomenclatur
primari
determin
posit
posit
interestingli
align
nine
natur
substrat
cleavag
site
pr
show
high
sequenc
divers
suggest
broad
proteolyt
specif
beck
et
al
report
use
hexapeptid
phage
librari
unravel
pr
specif
develop
new
proteas
inhibitor
tabl
librari
construct
fuse
mab
epitop
upstream
random
sequenc
phage
first
incub
pr
uncleav
phage
remov
addit
pansorbin
cell
biopan
select
highli
divers
sequenc
consist
suggest
broad
substrat
specif
proteas
howev
none
select
peptid
correspond
polyprotein
cleavag
site
nonetheless
sever
phagedisplay
peptid
effici
cleav
proteas
peptid
format
display
km
valu
lower
one
determin
peptid
mimick
natur
substrat
matrixcapsid
junction
tabl
ital
potent
select
substrat
cleav
time
effici
km
valu
ie
time
lower
natur
substrat
km
interestingli
substrat
display
two
residu
bold
optim
cleavag
site
model
design
base
frequent
select
residu
posit
tabl
sequenc
correspond
four
potent
substrat
synthes
peptid
transit
state
analogu
present
inhibitori
activ
nanomolar
rang
tabl
underlin
sequenc
author
appli
phage
substrat
approach
compar
rel
specif
human
felin
fiv
immunodefici
viru
pr
hexapeptid
specif
process
two
proteas
well
peptid
cleav
enzym
identifi
mutat
analysi
synthet
peptid
deriv
sequenc
process
effici
two
proteas
perform
assess
influenc
amino
acid
substitut
catalyt
process
pr
tabl
underlin
sequenc
show
substitut
val
posit
increas
cleavag
proteas
wherea
introduct
val
posit
favor
fiv
proteas
activ
particular
vvngl
inhibitor
identifi
first
studi
activ
pr
differ
potenc
replac
amid
group
hydroxyethylen
group
result
peptid
equival
inhibitori
activ
toward
fiv
proteas
parallel
epitop
map
inhibitor
discoveri
enzym
profil
applic
bacteriophag
particl
exploit
carrier
develop
vaccin
particular
purpos
phage
use
affin
select
tool
rather
display
antigen
immun
system
aim
elicit
specif
neutral
antibodi
orand
effici
cytotox
tcell
respons
inde
phage
also
consid
biolog
inert
particl
character
dens
repetit
organ
capabl
display
wide
rang
exogen
protein
precis
valenc
control
manner
moreov
phage
shown
natur
immunostimulatori
particularli
afford
easi
rapid
produc
administ
mani
anim
model
altogeth
characterist
make
bacteriophag
suitabl
valuabl
carrier
vaccin
develop
vaccin
trial
elicit
humor
cellular
respons
variou
protein
envelop
protein
well
rt
protein
conduct
larg
divers
bacteriophag
includ
lambda
phage
tabl
numer
phagevaccin
trial
use
mimotop
identifi
antibodi
report
see
tabl
attempt
aim
mainli
elicit
antibodi
direct
genuin
epitop
exist
antibodi
besid
descript
studi
exclus
dedic
use
phage
particl
vehicl
display
fragment
complet
protein
immun
system
prime
new
immun
respons
pioneer
attempt
report
minenkova
et
al
immun
rabbit
filament
phage
particl
display
small
peptid
gedrw
deriv
gag
protein
fusion
piii
minor
coat
protein
elicit
product
specif
igg
react
natur
antigen
well
gag
precursor
protein
shortli
afterward
two
studi
report
mice
immun
fd
phage
display
loop
fuse
piii
protein
induc
high
titer
antibodi
crossreact
loop
differ
strain
featur
neutral
activ
major
coat
protein
pviii
fd
phage
copi
per
particl
also
investig
scaffold
protein
vaccin
immun
phage
display
pviiifus
peptid
correspond
residu
rt
result
induct
specif
cytotox
cell
respons
ctl
display
peptid
prime
nevertheless
requir
coimmun
thelper
epitop
protein
kdswtvndiqklvgk
provid
either
separ
phage
particl
recent
attempt
prime
ctl
respons
conduct
phage
display
mixtur
thousand
variant
ctl
epitop
xgxgxaxvxi
deriv
loop
residu
rgpgrafvti
present
immunoglobulin
vh
domain
scaffold
mice
immun
provid
potent
broad
epitopespecif
long
last
respons
month
effector
memori
cell
induc
moreov
recent
studi
demonstr
mice
immun
variabl
epitop
librari
capabl
neutral
half
subtyp
b
viral
isol
use
challeng
includ
isol
known
resist
neutral
sever
potent
monoclon
antibodi
although
versatil
easi
manipul
filament
phage
present
limit
vaccin
name
low
display
level
limit
size
foreign
peptid
incorpor
without
interf
natur
function
phage
coat
protein
therefor
altern
bacteriophag
model
explor
phage
two
accessori
capsiddecor
protein
soc
hoc
demonstr
particularli
effici
high
copi
display
variou
larg
antigen
contrast
piii
pviii
protein
soc
hoc
present
major
advantag
dispens
phage
assembl
yet
abl
strongli
bind
outer
surfac
capsid
ad
subsequ
soc
hoc
selfassoci
capsid
display
level
copi
per
capsid
far
higher
densiti
filament
minor
coat
protein
copi
hoc
protein
provid
highdens
display
singl
well
multipl
antigen
immun
mice
elicit
strong
humor
cellular
respons
moreov
fusion
differ
antigen
soc
hoc
offer
possibl
develop
multicompon
vaccin
particl
phage
display
loop
protein
fuse
soc
protein
report
elicit
antibodi
capabl
recogn
nativ
antigen
studi
demonstr
hoc
protein
also
use
display
variou
antigen
includ
nef
trimer
peptid
deriv
cterminu
recent
lambda
phage
decor
capsid
protein
use
dens
display
glycosyl
mammalian
cellderiv
trimer
protein
lambda
phage
provid
display
level
copi
trimer
per
particl
higher
display
observ
nativ
virion
spike
per
virion
rabbit
immun
trial
rather
disappoint
higher
antibodi
titer
elicit
anim
receiv
solubl
oligomer
result
propos
due
sequenti
immun
process
strong
immunodomin
respons
phage
capsid
protein
probabl
boost
upon
sequenti
immun
could
lead
decreas
humor
immun
respons
display
antigen
viru
like
particl
vlp
deriv
bacteriophag
coat
protein
display
loop
devoid
phage
genom
also
report
although
character
low
display
level
copi
per
vlp
particl
nevertheless
abl
elicit
high
titer
specif
antibodi
inject
mice
provid
neutral
activ
sera
dilut
recent
phagederiv
vlp
display
loop
use
immun
mice
provid
hightit
antibodi
respons
aid
first
describ
two
year
later
caus
agent
isol
phage
display
technolog
first
publish
almost
concomitantli
protagonist
live
parallel
live
burton
et
al
identifi
human
fab
recogn
site
phage
display
first
antibodi
turn
one
rare
bntab
character
date
mani
studi
still
ongo
set
scaffold
present
epitop
conform
capabl
elicit
ab
inhibit
properti
articl
start
point
dens
literatur
exploit
differ
applic
phage
display
technolog
gain
much
knowledg
possibl
infect
process
complex
hideandseek
game
hiv
host
immun
system
absenc
effici
vaccin
candid
emphas
need
better
comprehend
immun
respons
identifi
antivir
molecul
best
knowledg
pathogen
four
applic
phage
display
technolog
describ
epitop
map
inhibitor
discoveri
substrat
present
carrier
phage
appli
parallel
improv
technolog
one
hand
crucial
discoveri
field
hand
like
account
tight
interplay
phage
display
technolog
appli
provid
preciou
knowledg
concern
region
recogn
ab
repertoir
immun
patient
allow
identifi
immunodomin
region
also
allow
map
epitop
numer
monoclon
antibodi
direct
viral
host
protein
importantli
discontinu
epitop
altern
phage
display
biopan
substract
procedur
epitop
mask
competit
antigen
pan
also
precis
highlight
nonimmunodomin
region
antigen
remain
occult
use
classic
biopan
approach
although
antibodi
identifi
epitopemask
mostli
devoid
neutral
activ
strategi
led
identif
fab
bind
high
affin
specif
target
take
advantag
affin
approach
aim
engin
bispecif
antibodi
coupl
inhibitor
toxin
multimer
increas
bind
avid
could
lead
develop
antivir
compound
effici
vaccin
candid
although
highli
inform
immun
trial
perform
mimotopesphagotop
select
phage
display
remain
altogeth
rather
disappoint
longlast
neutral
respons
report
provid
yet
proof
antigen
necessarili
impli
immunogen
among
bottleneck
field
vaccin
research
develop
weak
immunogen
properti
identifi
mimotop
nativ
antigen
whether
difficulti
elicit
andor
isol
strong
broad
neutral
antibodi
patient
normal
progressor
ltnp
caveat
phage
display
real
reflect
restrict
humor
respons
fight
hiv
remain
establish
nevertheless
discrep
exclus
mimotop
observ
antigen
fundament
prospect
use
phagedisplay
igm
librari
model
ab
close
germlin
ab
allow
elegantli
expor
poorli
character
determin
initi
antivir
immun
respons
phage
display
also
contribut
better
knowledg
structur
divers
protein
well
gain
insight
nonstructur
protein
involv
replic
mechan
highlight
exampl
would
phage
substrat
approach
allow
precis
character
proteas
cleavag
specif
therebi
provid
valuabl
inhibitor
candid
unravel
viral
replic
step
protein
interact
led
exploit
phage
display
engin
variou
type
inhibitor
target
either
viral
host
protein
parallel
phage
display
allow
identif
variou
type
inhibitor
target
either
viral
host
protein
nevertheless
strong
antivir
candid
broad
neutral
activ
andor
potenc
nanomolar
even
picomolar
rang
identifi
phage
display
technolog
present
inhibit
activ
rang
best
micromolar
rang
could
exploit
potent
inhibitor
origin
fab
librari
deriv
asymptomat
patient
whose
reactiv
previous
assess
immun
camelid
vhh
anti
inhibitor
identifi
semisynthet
ligand
analogu
random
peptid
librari
dpeptid
affin
improv
secondari
librari
inhibitor
select
differ
target
env
protein
coreceptor
biopan
carri
use
differ
type
support
immobil
protein
cell
peptid
illustr
power
versatil
phage
display
technolog
figur
despit
variabl
success
phage
display
technolog
per
se
develop
direct
antivir
agent
immun
respons
technolog
continu
contribut
preciou
otherwis
inaccess
develop
field
research
mainli
owe
abil
phage
display
high
densiti
either
singl
antigen
librari
antigensmimotop
regard
phage
extens
explor
increas
immun
respons
latest
develop
includ
exploit
phage
dna
vaccin
carrier
hybrid
phage
pursu
symbiot
interplay
phage
display
